St. Jude Medical Inc. and the company that is acquiring it, Abbott Laboratories, are selling several vascular closure product lines to Terumo Corp. of Japan in a $1.1 billion deal.
The deal with Terumo hinges on the completion of Abbott's $25 billion purchase of St. Jude Medical and will not take place if that larger deal falls apart. It also hinges on approval from antitrust regulators and is seen as a step to ease competitive concerns from the overlap of Abbott and St. Jude in certain products.
The transaction includes St. Jude Medical's Angio-Seal and Femoseal vascular closure products and Abbott's Vado Steerable Sheath. Abbott will retain its vascular closure products.
When put together, Abbott and St. Jude Medical will have products in nearly every area of the cardiovascular market. Abbott expects to close its purchase of St. Jude Medical, based in Little Canada, by the end of the year.
Abbott also said it expects to mitigate any impact to its profit because of the sale of the vascular closure products to Terumo.
A Chinese ship remains the focus of the investigation into Baltic Sea gas pipeline damaged last year
TikTok has promised to sue over the potential US ban. What's the legal outlook?
The summer after Barbenheimer and the strikes, Hollywood charts a new course
Stock market today: Wall Street tumbles after dispiriting data on the economy, as Meta sinks
